Background
Methods
Data collection
Definitions
Statistical analysis
Results
No. of patients | % | |
---|---|---|
Age at breast cancer diagnosis | ||
≤ 35 | 41 | 14.6 |
36–40 | 82 | 29.3 |
41–45 | 157 | 56.1 |
Height- median; range (cm) | 159 (141–175) | |
Weight- median; range (kg) | 54.6 (39.0–89.0) | |
BMI at diagnosis (according to HK BMI) | ||
Underweight (<18.5) | 33 | 11.8 |
Normal (18.5–22.9) | 155 | 55.4 |
Overweight (23.0–24.9) | 46 | 16.4 |
Obese (>25) | 46 | 16.4 |
1 or more children born before breast cancer diagnosis | 205 | 73.2 |
Ever smoking | 10 | 3.6 |
Ever excessive alcohol intake (> 2 units/day) | 1 | 0.4 |
Education | ||
Primary | 47 | 16.9 |
Secondary | 187 | 67.0 |
Tertiary | 27 | 9.7 |
Higher qualification | 18 | 6.5 |
Employment | ||
Retired | 3 | 1.1 |
Unemployed | 105 | 37.5 |
Full Time | 127 | 45.3 |
Part Time | 45 | 16.1 |
Family income | ||
< HK$5000 | 27 | 9.6 |
HK$5000–25,000 | 150 | 53.6 |
HK$25000–50,000 | 83 | 29.6 |
HK$50,000 | 20 | 7.2 |
1st degree relative with breast cancer | 17 | 6.1 |
T stage | ||
T1 | 140 | 50.0 |
T2 | 133 | 47.5 |
T3 | 7 | 2.5 |
T4 | 0 | 0 |
Nodal Status- positive | 114 | 40.7 |
TNM staging: | ||
Stage I | 88 | 31.4 |
Stage II | 165 | 58.9 |
Stage IIIa | 27 | 9.6 |
ER positive | 203 | 72.5 |
PR positive | 187 | 66.8 |
HER2 over-expression | 47 | 16.8 |
Breast surgery: | ||
Lumpectomy | 95 | 33.9 |
Mastectomy | 185 | 66.1 |
Axillary lymph node dissection | 276 | 98.6 |
Received adjuvant radiotherapy | 186 | 66.4 |
Adjuvant chemotherapy regimen: | ||
Non-anthracycline and non-taxane containing | 17 | 6.1 |
Anthracycline-containing | 184 | 65.7 |
Taxane-containing | 5 | 1.8 |
Anthracycline- and taxane-containing | 74 | 26.4 |
Duration of adjuvant chemotherapy >64 days | 191 | 68.2 |
Received corticosteroid premedication during chemotherapy | 258 | 92.1 |
Received adjuvant tamoxifen | 214 | 76.4 |
Received adjuvant trastuzumab | 8 | 2.9 |
Use of traditional Chinese medicine since diagnosis | 83 | 29.6 |
Body weight and BMI at breast cancer diagnosis and at study entry
Incidence of hypertension at breast cancer diagnosis and at study entry
Lipid profiles at study entry
Analysis for risk factors associated with weight gain, hypertension and dyslipidaemias after adjuvant chemotherapy
Univariate analysis | Multivariate analysis | |||||
---|---|---|---|---|---|---|
OR | 95% CI for OR | p | OR | 95% CI for OR |
p
| |
Age at diagnosis | 0.529 | 0.365–0.766 | 0.0007 | 0.459 | 0.309–0.683 | 0.0001 |
≤ 35 | 1 | - | - | |||
36–40 | 0.767 | 0.316–1.861 | 0.5575 | |||
41–45 | 0.332 | 0.149–0.741 | 0.0072 | |||
>/= 1 children before breast cancer diagnosis | 0.751 | 0.428–1.315 | 0.3160 | |||
1st degree relative with breast cancer | 1.425 | 0.488–4.167 | 0.5173 | |||
ER positive | 0.975 | 0.566–1.682 | 0.9282 | |||
PR positive | 1.211 | 0.726–2.022 | 0.4632 | |||
HER2 over-expression | 1.032 | 0.538–1.981 | 0.9238 | |||
Received adjuvant radiotherapy | 1.352 | 0.812–2.250 | 0.2466 | |||
Received adjuvant taxane-containing chemotherapy | 1.903 | 1.073–3.374 | 0.0278 | 2.041 | 1.127–3.696 | 0.0186 |
Duration of adjuvant chemotherapy >64 days | 1.904 | 1.137–3.189 | 0.0143 | |||
Received corticosteroid premedication during chemotherapy | 1.605 | 0.608–4.237 | 0.3390 | |||
Received adjuvant tamoxifen therapy | 1.366 | 0.778–2.398 | 0.2781 | |||
Received adjuvant trastuzumab | 0.969 | 0.227–4.140 | 0.9660 | |||
Use of traditional Chinese medicine since diagnosis | 1.303 | 0.758–2.239 | 0.3384 | |||
Education | 1.299 | 0.850–1.987 | 0.2271 | |||
Primary school | 1 | - | - | |||
Secondary school | 1.447 | 0.757–2.766 | 0.2642 | |||
Tertiary school + Higher qualification | 1.669 | 0.718–3.878 | 0.2336 | |||
Employment- Working | 0.954 | 0.579–1.572 | 0.8531 | |||
Family income </= HK$ 25,000 | 1.388 | 0.832–2.315 | 0.2097 | |||
Ever Smoker | 0.374 | 0.103–1.357 | 0.1348 | |||
Ever excessive alcohol intake (>2 units/day) | - | - | 0.9868 | |||
Chemotherapy-related amenorrhea | 2.375 | 1.034–5.435 | 0.0414 | 3.472 | 1.395–8.621 | 0.0074 |
Post/peri- menopausal at study entry | 0.666 | 0.408–1.085 | 0.1023 | |||
Age at study entry | 0.593 | 0.429–0.819 | 0.0015 | |||
≤ 40 | 1 | - | ||||
41–45 | 0.755 | 0.297–1.923 | 0.5561 | |||
46–50 | 0.467 | 0.198–1.102 | 0.0822 | |||
> 50 | 0.185 | 0.059–0.580 | 0.0038 |
Univariate analysis | Multivariate analysis | |||||
---|---|---|---|---|---|---|
OR | 95% CI for OR |
p
| OR | 95% CI for OR |
p
| |
Age at diagnosis | 1.243 | 0.869–1.779 | 0.2343 | |||
≤ 35 | 1 | - | ||||
36–40 | 1.000 | 0.429–2.331 | 1.0000 | |||
41–45 | 1.417 | 0.658–3.050 | 0.3727 | |||
>/= 1 children before breast cancer diagnosis | 1.291 | 0.715–2.332 | 0.3695 | |||
1st degree relative with breast cancer | 0.926 | 0.316–2.715 | 0.8885 | |||
ER positive | 0.517 | 0.298–0.895 | 0.0186 | 0.552 | 0.311–0.980 | 0.0423 |
PR positive | 0.712 | 0.419–1.213 | 0.2115 | |||
HER2 over-expression | 1.187 | 0.610–2.309 | 0.6134 | |||
Received adjuvant radiotherapy | 0.866 | 0.508–1.477 | 0.5984 | |||
Received adjuvant taxane-containing chemotherapy | 0.887 | 0.501–1.568 | 0.6790 | |||
Duration of adjuvant chemotherapy >64 days | 0.828 | 0.483–1.420 | 0.4928 | |||
Received corticosteroid premedication during chemotherapy | 1.046 | 0.410–2.667 | 0.9251 | |||
Received adjuvant tamoxifen therapy | 0.557 | 0.313–0.990 | 0.0462 | |||
Received adjuvant trastuzumab | 1.352 | 0.316–5.789 | 0.6846 | |||
Use of traditional Chinese medicine since diagnosis | 0.947 | 0.542–1.655 | 0.8486 | |||
Education | 0.789 | 0.507–1.228 | 0.2936 | |||
Primary school | 1 | - | - | |||
Secondary school | 0.907 | 0.461–1.787 | 0.7784 | |||
Tertiary school + Higher qualification | 0.609 | 0.246–1.509 | 0.2840 | |||
Employment- Working | 0.815 | 0.485–1.369 | 0.4397 | |||
Family income </= HK$ 25,000 | 0.753 | 0.441–1.287 | 0.3000 | |||
Ever Smoker | 0.271 | 0.033–2.198 | 0.2214 | |||
Ever excessive alcohol intake (>2 units/day) | - | - | 0.9877 | |||
Chemotherapy-related amenorrhea | 0.778 | 0.329–1.838 | 0.5665 | |||
Post/peri- menopausal at study entry | 0.930 | 0.559–1.548 | 0.7808 | |||
Weight gain >2% at study entry | 1.095 | 0.644–1.864 | 0.7371 | |||
Total Cholesterol >/= 5.2 mmol/L | 1.475 | 0.865–2.516 | 0.1534 | |||
LDL Cholesterol >/= 2.6 mmol/L | 1.762 | 1.027–3.021 | 0.0396 | |||
HDL Cholesterol </= 1.0 mmol/L | 1.842 | 0.700–4.850 | 0.2160 | |||
Triglyceride >/=1.7 mmol/L | 1.568 | 0.867–2.836 | 0.1364 | |||
Overweight/obese at study entry | 2.751 | 1.608–4.707 | 0.0002 | 2.723 | 1.568–4.728 | 0.0004 |
Age at study entry | 1.173 | 0.852–1.614 | 0.3273 | |||
≤ 40 | 1 | - | ||||
41–45 | 1.929 | 0.738–5.037 | 0.1799 | |||
46–50 | 1.774 | 0.720–4.371 | 0.2126 | |||
> 50 | 2.057 | 0.623–6.794 | 0.2367 |
Univariate analysis | Multivariate analysis | |||||
---|---|---|---|---|---|---|
OR | 95% CI for OR |
p
| OR | 95% CI for OR |
P
| |
Total cholesterol: high (n = 93) vs normal (n = 178) | ||||||
Overweight/obese at study entry | 1.760 | 1.032–3.003 | 0.0379 | 1.764 | 1.013–3.073 | 0.0451 |
Age at study entry | 2.101 | 1.467–3.010 | <0.0001 | 2.093 | 1.461–2.997 | <0.0001 |
≤ 40 | 1 | - | ||||
41–45 | 1.490 | 0.494–4.489 | 0.4789 | |||
46–50 | 3.838 | 1.397–10.548 | 0.0091 | |||
> 50 | 7.020 | 1.989–24.772 | 0.0025 | |||
LDL cholesterol: high (n = 152) vs normal (n = 115) | ||||||
Received corticosteroid premedication during chemotherapy | 7.576 | 1.724–33.33 | 0.0074 | 5.747 | 1.264–26.32 | 0.0236 |
Received adjuvant tamoxifen | 0.388 | 0.209–0.720 | 0.0027 | 0.342 | 0.179–0.656 | 0.0012 |
Overweight/obese at study entry | 2.468 | 1.407–4.330 | 0.0016 | 2.560 | 1.410–4.649 | 0.0020 |
Age at study entry | 1.626 | 1.192–2.217 | 0.0021 | 1.625 | 1.165–2.266 | 0.0042 |
≤ 40 | 1 | - | ||||
41–45 | 0.963 | 0.420–2.212 | 0.9298 | |||
46–50 | 1.763 | 0.813–3.823 | 0.1510 | |||
> 50 | 5.383 | 1.493–19.407 | 0.0101 | |||
HDL cholesterol: low (n = 18) vs. normal (n = 251) | ||||||
Ever smoker | 4.357 | 0.836–22.707 | 0.0806 | 7.772 | 1.102–54.827 | 0.0397 |
Post/peri- menopausal at study entry | 3.881 | 1.243–12.114 | 0.0196 | 3.629 | 1.144–11.509 | 0.0286 |
Overweight/obese at study entry | 8.193 | 1.845–36.372 | 0.0057 | 7.786 | 1.742–34.795 | 0.0072 |
Triglyceride: high (n = 62) vs. normal (n = 209) | ||||||
Adjuvant taxane-containing chemotherapy | 2.040 | 1.124–3.704 | 0.0192 | 2.552 | 1.317–4.944 | 0.0055 |
Weight gain >2% | 2.258 | 1.171–4.355 | 0.0150 | 2.213 | 1.084–4.517 | 0.0292 |
Overweight/obese at study entry | 2.306 | 1.282–4.149 | 0.0053 | 2.775 | 1.446–5.325 | 0.0021 |
Age at study entry | 1.641 | 1.118–2.410 | 0.0114 | 1.969 | 1.285–3.017 | 0.0019 |
≤ 40 | 1 | - | ||||
41–45 | 1.355 | 0.401–4.573 | 0.6246 | |||
46–50 | 2.558 | 0.842–7.773 | 0.0978 | |||
> 50 | 3.733 | 0.964–14.461 | 0.0566 |